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ABSTRACT 
A  major  problem   in   ocular  therapeutics   is   the  attainment   of  optimal   drug concentration at the site of action which is 
compromised mainly due to precorneal      loss  resulting in  only a  small  fraction  of the drug being ocularly absorbed.  The effective 
dose administered may be altered by increasing the retention time of medication into the eye by using ocular inserts for treating various 
ocular diseases. The aim of the present study was to prepare and evaluate novel Ocular inserts of Ketorolac Tromethamine with polymers like 
HPMC K4M, PVA, Locust Bean Gum and Modified Locust Bean Gum with Glycerol as plasticizer by film casting method. Nine formulations 
of ocular inserts based on Comaprision Study On the basis of In vitro release studies & physicochemical parameters, the formulation MOG 
sustained with maximum cumulative of 97.244% for a period 12 hr and it was found to be better than other formulations; hence MOG 2% was 
selected as optimized formulation. In vitro drug release kinetic data revealed that all formulation followed near to zero order release kinetics, 
involving in the all formulation drug release by Super Case-II type of diffusion. Optimized formulation (MOG 12%) passed the test for sterility 
and in stability studies no change of physiological properties.  On the basis  of the present  study,  the ocular  inserts  of Ketorolac 
Tromethamine  gives  promising  future  for  the  ophthalmic  drug  delivery system. 
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INTRODUCTION: 
Ophthalmic drug delivery is one of the most interesting and 
challenging endeavors facing the pharmaceutical scienticts1. 
The eye as a portal for drug delivery is generally used for 
local therapy against systemic therapy in order to avoid risk 
of eye damage from high blood concentrations of the drug 
which is not intended. The unique anatomy, physiology and 
biochemistry of the eye render this organ impervious to 
foreign substances, thus presenting a constant challenge to 
the formulator to circumvent  the  protective  barrier  of  the  
eye without  causing  permanent  tissue damage. Drug 
absorption occurs through corneal and non-corneal  
pathways. Most non- corneal absorption occurs via the 
nasolacrimal duct and leads to non-productive systemic 
uptake, while most drugs transported through the cornea is 
taken up by the targeted intraocular tissue. Unfortunately, 
corneal absorption is limited by drainage of the instilled 
solutions, lacrimation, tear turnover, metabolism, tear 
evaporation, non- productive absorption, adsorption and 
limited corneal area, poor corneal permeability, binding by 
the lacrimal proteins, enzymatic degradation, and the corneal 
epithelium itself.  These  limitations  confine  the  absorption  
window  to a  few  minutes  afte administration and reduce 
corneal absorption to less than 5%. Drugs administered into 
the eye are rapidly and totally absorbed. However, contrary 
to this belief, the moment drug is placed in the lower cul-de-
sac of eye, several factors immediately begin to affect the 
bioavailability of drug absorption of drugs takes place either 
through corneal or non corneal routes. The non corneal route 
involves absorption across the sclera and conjunctiva into 
the intraocular tissues. This route is however not productive 
as it restrains the entry of drug into aqueous humor. 
Maximum  absorption  thus  takes  place through  cornea  
which  leads  the  drug into aqueous humor. 
The mechanism of controlled drug release into the eye is as 
follows: 
(A) Diffusion   (B) Osmosis   (C) Bio-erosion. 
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Advantages of Ocular Insert 
Increased ocular residence, hence a prolonged drug activity 
and a higher bioavailability with respect to standard 
vehicles. Possibility of releasing drugs at a slow, constant 
rate. 
MATERIALS AND METHOD: 
Ketorolac tromethamine was received as a gift sample from 
Sun Pharma Baroda, LBG was received from chem. Dyes 
Rajkot, All the solvents used were of analytical grade. 
 
 
INGREDIENTS 
 
KT1 
 
KT2 
 
KT3 
Ketorolac 
Tromethamine(mg) 
 
495 
 
495 
 
495 
Modified Locust Bean %  
1.5 
 
2 
 
2.5 
 
Glycerol % 
 
30 
 
30 
 
30 
 
Distilled Water (ml) 
 
Upto 45ml 
 
Upto 45ml 
 
Upto 45ml 
 
Ocular Inserts were preferably formulated using the solvent 
casting method, whereby the water soluble ingredients were 
dissolved to form a clear viscous solution and the drug along. 
with other excipients was dissolved in a suitable solvent 
then both the solutions were mixed and stirred and finally 
casted into the Petri plate and dried. 
Modified Locust bean gum was prepared by 
Carboxymethylation process. 
Table 1. Formulation of ocular insert by different polymers. 
Interaction Studies: Interaction studies were conducted on 
the optimized formulations by comparing them with the 
pure drug and the placebo films. Drug-polymer compatibility  
was  confirmed  by  ultraviolet,  infrared and thin layer 
chromatography analysis. 
PHYSIOCHEMICAL EVALUATION OF OCULAR INSERTS 
1.   Thickness Determination: Thickness of the insert 
was measured at different points using digital 
micrometer screw gauge (Mitutoyo, Japan) and mean 
film thickness was noted6 . 
2.   Weight  Uniformity:  Ocular  inserts  were  taken 
from different areas of the film and weighed 
individually. The mean weight of insert was noted7. 
3. Folding Endurance: The folding endurance is expressed  
as  the  number  of  folds  (number  of times the insert 
is folded at the same place, either to break the 
specimen or to develop visible cracks)8. The insert was 
folded in the centre, between the fingers and the 
thumb and then opened. This was termed as one 
folding. The total folding operations was  named as 
folding endurance value. 
4.   Drug Content:  The  ocular  inserts  from  different areas 
of the film were taken. Drug content was estimated by 
triturating the ocular insert in 50ml of methanol with the 
help of a mortar and pestle. The solution was filtered 
through whatman no.42 filter paper and drug content 
determined by UV- Visible spectrophotometer method. 
5.   In  vitro  Drug  Diffusion  Studies:  In  vitro  drug 
release studies were carried out using a Franz diffusion cell. 
Ocular inserts were placed in the donor compartment over 
the dialysis membrane. 11
  
0.7 ml of isotonic phosphate 
buffer of pH 7.4 was placed in the donor chamber, which 
acted as the tear fluid. 20ml of isotonic phosphate buffer 
was taken as the receptor medium and the apparatus was 
maintained at 37± 2
o
C being continuously stirred using a 
magnetic stirrer. The samples were withdrawn at regular 
intervals and analyzed at 313nm. 
6. Stability Studies:  The stability studies of   ocular 
inserts were conducted according ICH guidelines15. The 
ocular inserts were packed in blister (PVC-Aluminium) 
and stored at 40±0.5°C / 75±5% RH, 25°/60% RH, 40°C 
for 3 months. Samples were withdrawn on days 0, 30, 60 
and 90 and analyzed for   physico chemical properties, assay 
and drug release. 
7.   Surface pH Determination:- 
Inserts were left to swell for 5 hours on agar plate 
prepared by dissolving 2% (m/v) agar in warm simulated 
tear fluid (STF) sodium chloride: 0.670 g, sodium 
bicarbonate 0.200 g, calcium chloride 0.008 g, and 
purified water q.s. 100 g of pH 7.4 under stirring and then 
pouring the solution into Petri dish till gelling at room 
temperature. The surface pH was measured by means of a 
pH paper placedon the surface of swollen patch. 
8.   Percentage Moisture Loss:- 
The percentage moisture loss was carried out to check the 
integrity of the film at dry condition. The ocular inserts were 
pre weighed accurately and kept in desiccators containing 
100ml of saturated solution of aluminum chloride. After 3 
days, the films were taken out and weighed. 
 
9. Kinetic modelling: 
Zero order: Mt = M0 + k0t 
First order: lnMt = lnM0 + k1t 
Matrix (Higuchi Matrix) model:- Mt = M0 + k1t1/2 
Peppas-Korsmeyer Equation:- 
Log (Mt /M∞) = log k + n log t 
Hixson-Croswell Equation:- (%Unreleased)1/3 = kt 
10. Sterility Test:- 
Ultra-Violet radiation was used to sterilize the ocular inserts 
and sterility testing was carried out under aseptic 
conditions. Alternate thioglycolate and Soyabean casein 
digest media was used to check sterility of formulation. 
11. Comparison of dissolution profile 
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A model-independent method for comparison of two 
dissolution profiles is based on determination of difference 
factor f1 and similarity factor f2 which are calculated using 
following formulae: 
 
 
Where, 
n = number of dissolution time points 
Rt = dissolution value of the reference drug product at time t 
Tt = dissolution value of the test drug product at time t 
The guidelines adopted for interpreting f1 and f2 values are 
given in table 
Table 2. Comparison of f1 and f2 value 
Difference 
factor f1 
Similarity 
factor f2 
inference 
0 100 Dissolution profiles are 
identical 
≤ 15 ≥ 50 Similarity or equivalence 
of two profiles 
 
 
 
RESULT AND DISCUSSION: 
Table 3. Thickness, Folding endurance and Drug content of MOG 
 
Formulation 
 
 
Thickness 
(mm)* 
 
 
Folding Endurance* 
 
 
Drug Content (%)* MOG 
1.5 
0.11 ± 0.012 125 ± 3 91.33  ± 1.527 
MOG 
2 
0.22 ± 0.031 282 ± 8 97.33 ± 2.516 
MOG 
2.5 
0.34± 0.032 212 ± 6 95.05 ± 1.527 
 
Table 4. Thickness, Folding endurance and Drug content of hpmc k4m 
 
Formulation 
 
 
Thickness 
(mm)* 
 
 
Folding 
Endurance* 
 
 
Drug Content 
(%)* 
HPMC K4M 1.5 0.8 ± 0.08 126 ± 1 91.33  ± 1.19 
HPMC K4M 2 0.9 ± 0.065 198± 1 95.33 ± 2.63 
HPMC 2.5 0.11 ± 
0.045 
210 ± 1.5 97.05 ± 0.79 
 
Table 4. Percentage moisture loss and Percentage moisture absorption 
Formulations % Moisture loss* %Moisture Absorbption* 
HKT1 
 
 
 
 
1.29±0.54 2.38±0.57 
HKT2 1.76±0.52 2.51 ±1.04 
HKT3 2.39±0.94 2.58±1.18 
MKT1 2.54±1.16 2.73±0.52 
MKT2 2. 61±0.40 2.79±0.92 
MKT3 2.91±0.94 3.14±0.76 
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Figure 1.- Graph of % moisture loss and % moisture absorption 
 
The values of percentage moisture loss are shown in table 
5.11. Percentage moisture loss of all formulations is in range 
of 1.29±0.54  to 2.91±0.94. It was found that with the 
increase in the concentration of MOG there was increase in 
the percentage moisture loss. This was due to the 
hydrophilicity of the polymer. 
The  values  of  percentage  moisture  absorption  are  shown  
in  table  5.11.  Percentage moisture absorption of all 
formulations is in range of 2.38±0.57 to 3.14±0.76. It was 
found that with the increase in the concentration of MOG 
there was increase in the percentage moisture absorption. 
This was due to the hydrophilicity of the polymer. 
 
 
 
In vitro diffusion study: 
Table 5.- Comparison studies between MOG and HPMC K4M 
TIME MOG 2 HPMC K4M 2.5 
0 0.00 0.00 
1 12.303±0.278 12.819±0.310 
2 22.013±0.223 18.909±2.01 
3 32.499±0.13 32.909±0.455 
4 41.401±0.080 39.536±1.340 
5 49.332±0.554 46.02±0.436 
6 57.839±0.536 52.375±0.1 
7 67.431±0.486 62.672±1.035 
8 75.217±0.557 71.486±0.432 
9 85.223±0.994 82.612±0.530 
10 92.25±0.607 87.622±0.999 
11 95.181±0.390 96.957±0.969 
12 97.458±1.452 98.987±0.49 
 
 
Fig 2. Comparison study of MOG and HPMC 
 
CONCLUSION:  
From this comparison data of HPMC K4M and MOG we can assume that both gives drug release at 12 hrs but MOG graph is more 
linear as compared to HPMC K4M graph. 
Table 6. Kinetic model of all formulation 
Formulation Zero 
order 
R2 
First 
order 
R2 
Higuchi 
model 
R2 
Korsemeyer-
peppas R2 
N 
value 
Hixon-
Crowell 
R2 
HKT1 0.894 0.491 0.99 0.593 0.5 0.988 
HKT2 0.960 0.611 0.978 0.705 0.70 0.93 
HKT3 0.993 0.675 0.941 0.78 0.784 0.924 
MKT1 0.979 0.597 0.96 0.679 0.67 0.955 
MKT2 0.986 0.660 0.954 0.780 0.780 0.964 
MKT3 0.989 0.817 0.88 0.874 0.874 0.94 
 
0
2
4
HKT1 HKT2 HKT3 MKT1 MKT2 MKT3
Axis Title 
% Moisture loss and %Moisture absorption of HKT1-MKT3 
Formulation 
% Moisture Loss
% Moisture Absorption
0
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100
150
0 5 10 15
%
 C
D
R
 
Time (hrs) 
MOG & HPMC K4M, 
MOG 2
HPMC 2.5
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Figure 3.:-Kinetic model of   Zero order 
 
Figure 5.24:-Kinetic model of   F irst order 
 
Figure 4.:-Kinetic model of   Higuchi release model 
 
Figure 5.:-Kinetic model of   Korsmeyers-Peppas model 
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Figure 6.:-Kinetic model of   Hixon Crowel model 
 
 
Fig 7. Photograph of MOG ocular insert   Fig 8. Photograph of HPMCocular insert 
 
COMPARISION STUDY OF THEORETICAL AND TWO OPTIMIZED DRUG RELEASE PROFILE 
Table 7. Comparison of theoretical value with HPMC and MOG 
Time Theoretical Value HPMC 2.5 MOG2 
1 8.33 12.819 12.30 
2 16.66 18.909 22.013 
3 24.99 32.909 32.499 
4 33.32 39.536 41.401 
5 41.65 46.02 49.332 
6 49.98 52.375 57.839 
7 58.31 62.672 67.431 
8 66.64 71.486 75.217 
9 74.97 82.612 85.223 
10 83.30 87.622 92.25 
11 91.63 96.957 95.181 
12 99.96 98.987 97.458 
Average Avg- 54.145 Avg-58.57 Avg-62.97 
 
*f1  value between 0-15 shows less difference in dissolution profile of reference (Rt) and test product (Tt). 
*f2 value should be between 0 and 100. It is 100 when two comparative groups of reference and test are identical and 
approaches to 0 as the dissimilarity increases. 
f1& f2 values were found to be 8.18 & 66.5,  for HKT3 and 12.06, 58 for MKT2Which showed more optimized than HKT3 
MKT2) had similarity with theoretical dissolution profile. So, it was identical 
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Figure 8.- Comparison graph between Theoretical batch and HKT3 
 
Figure 5.29:- Comparison graph between theoretical batch and MKT2 
Table 8. Simmilarity and dissimilarity factor of HKT3 and MKT2 
Formulation Drug Release Study F1 F2 
HKT3 In Vitro Diffusion Study 8.18 66.5 
MKT2 In Vitro Diffusion Study 12.06 58 
 
Stability test: 
A short term stability study was carried out. A sufficient number of optimized ocular inserts  (packed  in  aluminum  foil) 
were  stored  in  the stability chamber at temperature 40ºC and 75% RH for 1 month. After a month the ocular inserts were 
taken out and were evaluated for thickness, folding endurance and % in vitro drug release at 12
th 
hour. 
Table no 9.:- Evaluation parameters for stability study 
Formulation Days Parameters evaluated for the stability study 
Physical 
appearance 
Thickness Folding 
endurance 
%CDR 
 
 
HKT3 
0 Smooth, opaque 0.11 ± 0.032 210 ±1.52 98.987±0.49 
15 Smooth, opaque 0.13 ± 0.045 221 ±1.49 96.611 ±0.39 
30 Smooth, opaque 0.12 ± 0.037 222 ±0.96 97.6 23±1.28 
Formulation Days Parameters evaluated for the stability study 
Physical 
appearance 
Thickness Folding 
endurance 
%CDR 
 
 
MKT2 
0 Smooth, 
transparent 
0.22 ± 0.068 452 ± 2.365 97.458±0.658 
15 Smooth, 
transparent 
0.21 ± 0.015 449 ± 1.658 96.325 ± 0.105 
30 Smooth, 
transparent 
0.20 ± 0.010 454 ± 2.365 97.698 ± 0.014 
 
-20
0
20
40
60
80
100
120
0 5 10 15
%
 C
D
R
 
Time(hrs) 
Comparision of drug release data HKT3 
Theoretical Batch (Rt)
HKT3
-20
0
20
40
60
80
100
120
0 5 10 15
%
 C
D
R
 
Time(HRS) 
Comparision of drug release data MKT2 
Theoretical Batch (Rt)
MKT2
Banerjee et al                                                                                               Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):232-239 
ISSN: 2250-1177                                                                                  [239]                                                                                 CODEN (USA): JDDTAO 
REFERENCES: 
1. 14.  P.Tangri, S.Khurana. , “ Basics Of Ocular Drug Delivery 
Systems” , International Journal of Research in Pharmaceutical 
and Biomedical Sciences, 2011. 
2. Reeta.Rani.Thakur, Mridul.Kashiv, “Modern Delivery Systems 
For Ocular Drug Formulations, A Comparative Overview WRT 
Conventional Dosage Form,  2011, 8-18. 
3. Geeta.Rajput, Shweta.Sharma, Shalini.Chaudhury, Banshraj, 
“Review on Ophthalmic Inserts, International Journal of 
Pharma Professional Research, 2014, 1052-1060. 
4. Thakur.Richa, Swami.Gaurav, Promising Implication of 
Ocusert in Ocular Diseases, Journal of Drug Delivery and 
Therapeutics, 2012, 18-25. 
5. Rathore.K.S, Nema.R.K, “Review on Ocular Insert, International 
Journal of Pharma Tech and Research, 2009, 2, 164-169. 
6. Asija Rajesh, Dadarwal Poonam, Asija sangeeta, “Ocular drug 
delivery system”, International journal of universal pharmacy 
and biosciences, 2012, 2, 390-39. 
7. N.K S, S.K banerjee, D.D Gaikwad, S.L Jadhav, R.M Thoral, 
“Ocular insert review”, International journal of current 
research and review, 2011, 2, 1-58. 
8. Jayesh k Jethava, “Design formulation and evaluation of 
biosoluble polymeric sustained release ocular insert of 
Loteprednol Etabonate, 2014,2 1-142. 
9. Sharma. Reshu, Goswami . Laxmi, Kothiyal. Preeti, 
“Formulation and Evaluation of Ocular inserts of Acyclovir”, 
International Journal of Drug Research and Technology, 2013, 
4, 88-95. 
10. S.Ramkanth, C.Madhusudhana.Chetty, M.Alagusundaram, 
S.Angalaparameshwari, V.S.Thruvengadarajan and 
K.Ganaprakesh, “Design and Formulation of Diclofenac 
Ocusert” , International Journal of Pharma Tech Research, 
2009,4, 1219-1223. 
11. Patel . Dipti, Patel M.M, Patel.Manish, “Preaparion and 
Evaluation of Ocular Inserts Containing Brimonidine 
Tartarate” , International Journal of Pharmaceutical and 
Clinical Research,  2009, 1, 19-22. 
12. Mohamed.A.Attia, Mohamed.AL-Azizi, Mohamed S.Hashish, 
“Design and Evaluation of Ocular Inserts of Ciprofloxacin 
Hydrochloride”, International Journal of Pharma Tech and 
Research,  2011,3,1750-1763. 
13. Venkateshwar.Rao, Somashekar.Shyale, “Department of 
Pharmaceutics,V.L.College of Pharmacy,Raichur,Karnataka, 
2002,34, 239-246. 
 
 
 
